Drug Profile
TP 1287
Alternative Names: TP-1287Latest Information Update: 22 Mar 2024
Price :
$50
*
At a glance
- Originator Tolero Pharmaceuticals
- Developer Sumitomo Pharma America
- Class Antineoplastics; Benzopyrans; Flavonoids; Piperidines; Small molecules
- Mechanism of Action Cyclin dependent kinase 9 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- No development reported Haematological malignancies; Sarcoma
Most Recent Events
- 22 Mar 2024 TP 1287 is still in phase I trials in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (PO) (Sumitomo Pharma pipeline, March 2024)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Sarcoma(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (PO)